<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00100</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 9 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Dilution fluid.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Butterfield's phosphate buffered  <!-- PJG 0012 frnewline --> water adjusted to pH 7.2 and containing an antimicrobial  <!-- PJG 0012 frnewline --> inactivator specific for the test formulation. Adjust pH with  <!-- PJG 0012 frnewline --> 0.1 Normal hydrochloric acid or 0.1 Normal sodium hydroxide.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 10 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Soybean-casein digest agar.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Supplemental polysorbate  <!-- PJG 0012 frnewline --> 80 (0.5 to 10 grams/liter) is to be added to the agar to  <!-- PJG 0012 frnewline --> stimulate the growth of lipophilic organisms. A suitable  <!-- PJG 0012 frnewline --> antimicrobial inactivator is also to be added.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 11 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Fingernail cleaning sticks <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> .  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 12 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sterile hand brushes (required only if specified for  <!-- PJG 0012 frnewline --> use with test formulation).  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Products that specify the use of a  <!-- PJG 0012 frnewline --> device in conjunction with the antimicrobial are to include this  <!-- PJG 0012 frnewline --> information in the product labeling. The device is an integral  <!-- PJG 0012 frnewline --> part of the study. If gauze is to be used, then the product  <!-- PJG 0012 frnewline --> labeling is to reflect this condition of use.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Test panelists.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Panelists shall consist of healthy  <!-- PJG 0012 frnewline --> adult male and female volunteers who have no evidence of  <!-- PJG 0012 frnewline --> dermatosis, have not received antibiotics or taken oral  <!-- PJG 0012 frnewline --> contraceptives 2 weeks prior to the test, and who agree to  <!-- PJG 0012 frnewline --> abstain from these materials as described in paragraph  <!-- PJG 0012 frnewline --> (b)(1)(iii)(D)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) of this section until the conclusion of the  <!-- PJG 0012 frnewline --> test.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (D)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of volunteers <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) At least 2 weeks  <!-- PJG 0012 frnewline --> prior to start of the test, enroll sufficient subjects per product being tested to satisfy the statistical criteria of the  <!-- PJG 0012 frnewline --> clinical trial design.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) Instruct the volunteers to avoid contact with  <!-- PJG 0012 frnewline --> antimicrobials (other than the test formulation) for the duration  <!-- PJG 0012 frnewline --> of the test. This restriction includes antimicrobial containing  <!-- PJG 0012 frnewline --> antiperspirants, deodorants, shampoos, lotions, soaps, and  <!-- PJG 0012 frnewline --> materials such as acids, bases, and solvents. Bathing in  <!-- PJG 0012 frnewline --> chlorinated pools and hot tubs is to be avoided. Volunteers are  <!-- PJG 0012 frnewline --> to be provided with a kit of nonantimicrobial personal care  <!-- PJG 0012 frnewline --> products for exclusive use during the test and rubber gloves to  <!-- PJG 0012 frnewline --> be worn when contact with antimicrobials cannot be avoided.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (E)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Selection of evaluable subjects.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> After panelists have  <!-- PJG 0012 frnewline --> refrained from using antimicrobials for at least 2 weeks, perform  <!-- PJG 0012 frnewline --> wash with baseline control soap. Subjects are not to have washed  <!-- PJG 0012 frnewline --> their hands 2 hours prior to the baseline count determination.  <!-- PJG 0012 frnewline --> After washing, determine the first estimate of the baseline  <!-- PJG 0012 frnewline --> population by sampling both hands and enumerating the bacteria in  <!-- PJG 0012 frnewline --> the sampling solution. This is day 1 of the ``baseline period.''  <!-- PJG 0012 frnewline --> Repeat this baseline determination on days 3 and 7, days 3 and 5,  <!-- PJG 0012 frnewline --> or days 5 and 7 of the ``baseline period'' to obtain three  <!-- PJG 0012 frnewline --> estimates of the baseline population. Any subjects exhibiting  <!-- PJG 0012 frnewline --> counts greater than or equal to 1.5X105 after the first and  <!-- PJG 0012 frnewline --> second estimates of the baseline populations are obtained can be  <!-- PJG 0012 frnewline --> assigned to products in accordance with the randomization plan  <!-- PJG 0012 frnewline --> described below. Sufficient evaluable subjects must be enrolled per arm to satisfy the statistical conditions of adequacy with at  <!-- PJG 0012 frnewline --> least 80 percent power and a test level of 5 percent.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (F)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Number of subjects.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The number of subjects required  <!-- PJG 0012 frnewline --> per arm of the study can be estimated from the following  <!-- PJG 0012 frnewline --> equation: n"2S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (Z <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> a/2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> +Z <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> b <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> /D <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,  <!-- PJG 0012 frnewline --> where:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> S2 is your estimate of variance;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Z <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> a/2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  corresponds to the level of the test; for a 5 percent  <!-- PJG 0012 frnewline --> test level = 1.96;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Z <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> b <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  corresponds to the power of the test; for 80 percent  <!-- PJG 0012 frnewline --> power = .842; and  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> D is the clinical difference of significance to be ruled  <!-- PJG 0012 frnewline --> out; say 20 percent of the active control's mean reduction from  <!-- PJG 0012 frnewline --> baseline at a specific time. For example, data from a number of glove juice studies  <!-- PJG 0012 frnewline --> submitted over the past few years to the agency as part of  <!-- PJG 0012 frnewline --> applications under part 314 of this chapter were reviewed to  <!-- PJG 0012 frnewline --> obtain information relative to the variance of the difference  <!-- PJG 0012 frnewline --> from baseline for count reduction data. For 128 standard  <!-- PJG 0012 frnewline --> deviations extracted, it was noted that 50 percent of the values  <!-- PJG 0012 frnewline --> are between .90 and 1.12; 25 percent are less than .90; and 25  <!-- PJG 0012 frnewline --> percent are greater than 1.12. The range is from .49 to 1.73,  <!-- PJG 0012 frnewline --> the 25th percentile standard deviation is 0.86, the median  <!-- PJG 0012 frnewline --> standard deviation is 1.01, and the 75th percentile standard  <!-- PJG 0012 frnewline --> deviation is 1.20. The larger the standard deviation, the larger  <!-- PJG 0012 frnewline --> the sample size required to rule out a difference of clinical  <!-- PJG 0012 frnewline --> importance. Assuming that the active control surgical hand scrub  <!-- PJG 0012 frnewline --> produces a mean log reduction of 2.5 at hour 3 and the test hand  <!-- PJG 0012 frnewline --> scrub is to be within 20 percent of this,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> i.e <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ., D=0.5, and if S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> =  <!-- PJG 0012 frnewline --> 1.02, then n=64 subjects per arm of the study. Because blocks of  <!-- PJG 0012 frnewline --> six are recommended, the sample size per arm is 66. The S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> =1.44  <!-- PJG 0012 frnewline --> corresponds to the 75th percentile in the data set. This gives a  <!-- PJG 0012 frnewline --> sample size of 90 subjects per arm. The total number of  <!-- PJG 0012 frnewline --> evaluable subjects required for a successful trial will depend  <!-- PJG 0012 frnewline --> upon the estimate of variance available and the number of  <!-- PJG 0012 frnewline --> products that need testing.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (G)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Study design.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A randomized, blinded, parallel arm  <!-- PJG 0012 frnewline --> design is to be used to test the products. Due to the nature of  <!-- PJG 0012 frnewline --> their constituents, some test surgical hand scrubs will require  <!-- PJG 0012 frnewline --> not only the use of an active control arm but also use of a  <!-- PJG 0012 frnewline --> vehicle control arm and perhaps a placebo control arm to  <!-- PJG 0012 frnewline --> demonstrate efficacy. The schematic layout of sampling  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> times is given in Table 1 as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            